Notice of Proposed Sale · 144
Enliven Therapeutics, Inc.
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Enliven Therapeutics, Inc.
- Issuer CIK
- 0001672619
- SEC file number
- 001-39247
- Phone
- 7206478519
- Person for whose account securities are to be sold
- Derynck Mika K
- Relationships to issuer
- Director
- Street
- 205 PARK ROAD
- City
- BURLINGAME
- State / country code
- CA
- Postal code
- 94010
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 158,795 | 9,216,461.80 | 71,000,000 | 08/04/2026 | NASDAQ | Jefferies LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Jefferies LLC
- Street
- 520 Madison Avenue, 4th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10022
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/09/2022 | Stock Options | Enliven Therapeutics | 87,373 | N | 08/09/2022 | N/A |
| Common | 02/23/2023 | Stock Options | Enliven Therapeutics | 27,567 | N | 02/23/2023 | N/A |
| Common | 02/13/2024 | Stock Options | Enliven Therapeutics | 23,364 | N | 02/13/2024 | N/A |
| Common | 02/06/2025 | Stock Options | Enliven Therapeutics | 20,491 | N | 02/06/2025 | N/A |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
All sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling Plan dated 04/08/2025, and all representations regarding material non-public information were made as of the adoption of the plan.
Notice signature
- Notice date
- 08/04/2026
- Signed
- Mika Derynck
- Plan adoption dates
- 04/08/2025
Company context
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven’s discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California. To learn more, visit www.enliventherapeutics.com and connect with us on LinkedIn and X.